Biology of ischemic cerebral cell death
Identifieur interne : 003776 ( Main/Exploration ); précédent : 003775; suivant : 003777Biology of ischemic cerebral cell death
Auteurs : Daniel L. Small [Canada] ; Paul Morley [Canada] ; Alastair M. Buchan [Canada]Source :
- Progress in Cardiovascular Diseases [ 0033-0620 ] ; 1999.
Abstract
With the approval of alteplase (tPA) therapy for stroke, it is likely that combination therapy with tPA to restore blood flow, and agents like glutamate receptor antagonists to halt or reverse the cascade of neuronal damage, will dominate the future of stroke care. The authors describe events and potential targets of therapeutic intervention that contribute to the excitotoxic cascade underlying cerebral ischemic cell death. The focal and global animal models of stroke are the basis for the identification of these events and therapeutic targets. The signalling pathways contributing to ischemic neuronal death are discussed based on their cellular localization. Cell surface signalling events include the activities of both voltage-gated K+, Na+, and Ca2+ channels and ligand-gated glutamate, gamma-aminobutyric acid and adenosine receptors and channels. Intracellular signalling events include alterations in cytosolic and subcellular Ca2+ dynamics, Ca2+-dependent kinases and immediate early genes whereas intercellular mechanisms include free radical formation and the activation of the immune system. An understanding of the relative importance and temporal sequence of these processes may result in an effective stroke therapy targeting several points in the cascade. The overall goal is to reduce disability and enhance quality of life for stroke survivors. Copyright © 1999 by W.B. Saunders Company Progress in Cardiovascular Diseases, Vol. 42, No. 3 (November/December), 1999: pp 185-207
Url:
DOI: 10.1016/S0033-0620(99)70002-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002382
- to stream Istex, to step Curation: 002382
- to stream Istex, to step Checkpoint: 001415
- to stream Main, to step Merge: 003D55
- to stream Main, to step Curation: 003776
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biology of ischemic cerebral cell death</title><author><name sortKey="Small, Daniel L" sort="Small, Daniel L" uniqKey="Small D" first="Daniel L." last="Small">Daniel L. Small</name></author><author><name sortKey="Morley, Paul" sort="Morley, Paul" uniqKey="Morley P" first="Paul" last="Morley">Paul Morley</name></author><author><name sortKey="Buchan, Alastair M" sort="Buchan, Alastair M" uniqKey="Buchan A" first="Alastair M." last="Buchan">Alastair M. Buchan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B48DF05771726B4024DF8B7FF69521CDBEC43EF3</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1016/S0033-0620(99)70002-2</idno><idno type="url">https://api-v5.istex.fr/document/B48DF05771726B4024DF8B7FF69521CDBEC43EF3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002382</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002382</idno><idno type="wicri:Area/Istex/Curation">002382</idno><idno type="wicri:Area/Istex/Checkpoint">001415</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001415</idno><idno type="wicri:doubleKey">0033-0620:1999:Small D:biology:of:ischemic</idno><idno type="wicri:Area/Main/Merge">003D55</idno><idno type="wicri:Area/Main/Curation">003776</idno><idno type="wicri:Area/Main/Exploration">003776</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Biology of ischemic cerebral cell death</title><author><name sortKey="Small, Daniel L" sort="Small, Daniel L" uniqKey="Small D" first="Daniel L." last="Small">Daniel L. Small</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Receptor and Ion Channels Group, Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada, and Clinical Neurosciences, University of Calgary, Foothills Hospital, Calgary</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Morley, Paul" sort="Morley, Paul" uniqKey="Morley P" first="Paul" last="Morley">Paul Morley</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Receptor and Ion Channels Group, Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada, and Clinical Neurosciences, University of Calgary, Foothills Hospital, Calgary</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Buchan, Alastair M" sort="Buchan, Alastair M" uniqKey="Buchan A" first="Alastair M." last="Buchan">Alastair M. Buchan</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Receptor and Ion Channels Group, Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada, and Clinical Neurosciences, University of Calgary, Foothills Hospital, Calgary</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Progress in Cardiovascular Diseases</title><title level="j" type="abbrev">YPCAD</title><idno type="ISSN">0033-0620</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1999">1999</date><biblScope unit="volume">42</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="185">185</biblScope><biblScope unit="page" to="207">207</biblScope></imprint><idno type="ISSN">0033-0620</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0033-0620</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With the approval of alteplase (tPA) therapy for stroke, it is likely that combination therapy with tPA to restore blood flow, and agents like glutamate receptor antagonists to halt or reverse the cascade of neuronal damage, will dominate the future of stroke care. The authors describe events and potential targets of therapeutic intervention that contribute to the excitotoxic cascade underlying cerebral ischemic cell death. The focal and global animal models of stroke are the basis for the identification of these events and therapeutic targets. The signalling pathways contributing to ischemic neuronal death are discussed based on their cellular localization. Cell surface signalling events include the activities of both voltage-gated K+, Na+, and Ca2+ channels and ligand-gated glutamate, gamma-aminobutyric acid and adenosine receptors and channels. Intracellular signalling events include alterations in cytosolic and subcellular Ca2+ dynamics, Ca2+-dependent kinases and immediate early genes whereas intercellular mechanisms include free radical formation and the activation of the immune system. An understanding of the relative importance and temporal sequence of these processes may result in an effective stroke therapy targeting several points in the cascade. The overall goal is to reduce disability and enhance quality of life for stroke survivors. Copyright © 1999 by W.B. Saunders Company Progress in Cardiovascular Diseases, Vol. 42, No. 3 (November/December), 1999: pp 185-207</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Alberta</li></region><settlement><li>Calgary</li></settlement><orgName><li>Université de Calgary</li></orgName></list><tree><country name="Canada"><region name="Alberta"><name sortKey="Small, Daniel L" sort="Small, Daniel L" uniqKey="Small D" first="Daniel L." last="Small">Daniel L. Small</name></region><name sortKey="Buchan, Alastair M" sort="Buchan, Alastair M" uniqKey="Buchan A" first="Alastair M." last="Buchan">Alastair M. Buchan</name><name sortKey="Morley, Paul" sort="Morley, Paul" uniqKey="Morley P" first="Paul" last="Morley">Paul Morley</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003776 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003776 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B48DF05771726B4024DF8B7FF69521CDBEC43EF3
|texte= Biology of ischemic cerebral cell death
}}
| This area was generated with Dilib version V0.6.29. |  |